Article

Co-promotion agreement covers aflibercept in Japan

Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin Ltd., and Santen Pharmaceutical Co. Ltd. have entered into a co-promotion agreement for aflibercept injection (Eylea, also known as VEGF Trap-Eye; Regeneron Pharmaceuticals) in Japan.

Tarrytown, NY-Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin Ltd., and Santen Pharmaceutical Co. Ltd. have entered into a co-promotion agreement for aflibercept injection (Eylea, also known as VEGF Trap-Eye; Regeneron Pharmaceuticals) in Japan.

In June 2011, Bayer Yakuhin submitted an application for marketing authorization to the Ministry of Health, Labor, and Welfare for aflibercept for the treatment of neovascular age-related macular degeneration (AMD).

Bayer HealthCare and Regeneron are collaborating on the global development of aflibercept, which was approved in the United States for the treatment of wet AMD in November. Regeneron maintains exclusive rights to aflibercept in the United States. Bayer HealthCare owns the exclusive marketing rights outside the United States. Bayer and Regeneron amended their existing global license and collaboration agreement for aflibercept to convert the 50/50 profit share for Japan into a royalty arrangement that approximates the economics of the profit split.

“With this agreement and upon marketing authorization, a newly formed Bayer Yakuhin ophthalmology field force and Santen, the leading ophthalmology company in Japan, will promote [aflibercept],” said Sebastian Guth, president and chief executive officer of Bayer Yakuhin, Ltd. “We expect that the combined resources of the two companies will allow [aflibercept] to achieve a broader and faster reach into the Japanese ophthalmology community and potentially benefit a greater number of patients.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.